The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 30, 2024
Filed:
Apr. 09, 2021
The Brigham and Women's Hospital, Inc., Boston, MA (US);
The Broad Institute, Inc., Cambridge, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
Vijay K. Kuchroo, Boston, MA (US);
Chao Wang, Boston, MA (US);
Aviv Regev, Cambridge, MA (US);
Karthik Shekhar, Cambridge, MA (US);
The Brigham and Women's Hospital, Inc., Boston, MA (US);
The Broad Institute, Inc., Cambridge, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
Abstract
Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.